← Back to All Filings

AstraZeneca Officer Files to Sell $1.3M in Vested Stock

Low SignificanceNovember 12, 2025 at 6:04:16 PM EST

ASTRAZENECA PLC

$AZN144CIK: 0000901832

Subscribe to track AZN

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

AstraZeneca Officer Files to Sell $1.3M in Vested Stock

Company: ASTRAZENECA PLC (AZN) Form: 144 | Filed: 2025-11-12 Significance: Low

Insider: ARADHANA SARIN Title: Officer | Relationship: Officer

Transaction: • Type: Proposed Sale • Shares: 15,000 • Price: ~$88.88 • Value: $1,333,200 • Owned After: Not Disclosed

Key Insight: An officer has filed a notice of proposed sale for shares acquired through a restricted stock vesting plan. The transaction value is negligible (<0.001%) compared to AstraZeneca's $271B market cap.

Market Context: This type of sale is common for executives to manage holdings from compensation and is generally not considered a significant market signal for a company of this size.

Comprehensive Analysis

SEC Filing Analysis: ASTRAZENECA PLC (AZN)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: An officer filed a notice of proposed sale for $1.33 million worth of stock, acquired as part of a compensation plan.
  • Market Impact: The transaction is negligible relative to the company's market capitalization and is unlikely to have any market impact.

Company Information

FieldValue
CompanyASTRAZENECA PLC
Ticker SymbolAZN
CIK0000901832
IndustryPharmaceutical Preparations

Insider Information

FieldValue
NameARADHANA SARIN
CIK0001729110
Title/PositionOfficer
RelationshipOfficer

Transaction Details

FieldValue
Form Type144
Transaction Date2025-11-12
Transaction CodeS
Security TypeADR
Shares Involved15,000
Price Per Share$88.88
Total Value$1,333,200
Shares Owned AfterNot Disclosed
Ownership TypeNot Disclosed

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$1,333,200
% of Market Cap0.0005%
Shares Transacted15,000
% of Shares Outstanding0.0005%
Post-Transaction OwnershipNot Disclosed
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: The $1.33 million proposed sale is trivial for a mega-cap company with a market capitalization of $271.24 billion.
  • Ownership Concentration: While post-transaction ownership is not disclosed, a sale of this size is highly unlikely to materially alter the insider's overall stake.
  • Dilution Impact: Not applicable, as this is a sale of existing shares, not an issuance.
  • Transaction Significance: The transaction is insignificant, representing a tiny fraction of both the market cap and shares outstanding. It is a routine filing for a corporate executive.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The sale is related to vested compensation from a restricted stock plan. Such sales are common for liquidity and tax purposes and do not typically reflect an insider's negative outlook on the company's future performance. The size is de minimis.

Volume & Sentiment

  • Expected Volume Impact: None. The transaction size is too small to have a noticeable effect on the daily trading volume of AZN.
  • Sentiment Indicator: Neutral. The market will likely view this as a routine, non-eventful filing.

Additional Context

Transaction Notes

  • The filing specifies the shares were acquired via "Restricted stock vesting under a registered plan" and the nature of payment was "Compensation". This strongly suggests the sale is a non-discretionary event to either cover taxes upon vesting or for personal liquidity planning.
Topics:#AstraZeneca#AZN#InsiderTrading#SECFiling#Form144#StockSale#ExecutiveComp#Pharma#Investing

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.